Article Information
vol. 16 no. 2
Published By
Print ISSN
Online ISSN
History
- Received March 20, 2020
- Accepted April 16, 2020
- Published online September 25, 2020.
Copyright & Usage
Copyright ©ERS 2020 Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Sandhya Khurana1⇑,
- Andrew Bush2 and
- Fernando Holguin3
- on behalf of the European Respiratory Society/American Thoracic Society Severe Asthma Task Force
- 1University of Rochester School of Medicine and Dentistry, Pulmonary and Critical Care Medicine, Rochester, NY, USA
- 2Dept of Paediatrics, National Heart & Lung Institute, Imperial College London, London, UK
- 3University of Colorado, Pulmonary Sciences and Critical Care Medicine, Denver, CO, USA
- E-mail: sandhya_khurana{at}urmc.rochester.edu
Article usage
Altmetrics
Vol 16 Issue 2
Table of Contents
Management of severe asthma: summary of the European Respiratory Society/American Thoracic Society task force report
Jump To
- Article
- Abstract
- Abstract
- Background
- The Severe Asthma Task Force of the ERS/ATS
- What questions did the task force consider?
- Should a monoclonal anti-IL5 or antil-IL-5 receptor α-subunit antibody be used in adults and children with severe asthma?
- Should a monoclonal anti-IL-4Rα be used in adults and children with severe asthma?
- Should a LAMA be used in adults and children with severe asthma?
- Should a macrolide be used in adults and children with severe asthma?
- Biomarkers in severe asthma
- Should a specific biomarker be used to initiate treatment with an anti-IL-5 therapy in severe asthma?
- Should measurement of a specific biomarker, in addition to total IgE level, be used to guide initiation of treatment with anti-IgE antibody in severe asthma?
- Conclusions and future perspectives
- Footnotes
- References
- Figures & Data
- Info & Metrics